ClonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma

In an effort to promote higher quality patient care, NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients. This article will explore the PQI in patients who are monitored with minimal residual disease (MRD) testing. This PQI in Action is a follow up to the clonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma PQI and explores how the medically integrated teams at Florida Cancer Specialists & Research Institute (FCS) and Rocky Mountain Cancer Centers incorporate the information found in the PQIs as part of their daily workflow. This article will discuss how utilizing the clonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma PQI elevates patient care.